Yale University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).

1,492 total trials 254 currently recruiting 1005 completed early-phase tilt top decile by trial count

Yale University: 1,492 sponsored US clinical trials, 254 recruiting.

Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.

Top-decile sponsor footprint

Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,492 total, page 22 of 30

COMPLETED

Intracranial Atherosclerosis and Depression After Coronary Artery Bypass Graft

NCT01838356
COMPLETED Phase 2

Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

NCT01931878
TERMINATED NA

Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations Results

NCT04548622
TERMINATED Phase 2

IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation

NCT01931865
COMPLETED Phase 3

A Trial of Cranberry Capsules for Urinary Tract Infection Prevention in Nursing Home Residents

NCT01691430
COMPLETED NA

A Couple-Based Relationship Strengthening HIV Intervention for Young Parents

NCT01643005
COMPLETED

Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis

NCT01661491
COMPLETED Phase 2

Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach

NCT02419313
TERMINATED NA

Comparison of Ultrasound-guided Versus Blind Insertion of Radial Artery Catheters

NCT01663779
COMPLETED Early Phase 1

Cannabinoid Augmentation of Fear Response in Humans

NCT01665573
COMPLETED NA

A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis

NCT01675232
COMPLETED Phase 2

N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder

NCT01172275
COMPLETED Phase 1

Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors

NCT01640665
COMPLETED NA

Teens-Connect: Preventive Psycho-education for Transitioning Teens With Diabetes

NCT01783327
COMPLETED

Point-of-Care Focused Cardiac Ultrasound in Assessing the Thoracic Aorta

NCT01671618
TERMINATED NA

Point-of-Care Ultrasound in the Emergency Department Evaluation of Syncope

NCT01671371
COMPLETED NA

Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm

NCT01699607
COMPLETED Early Phase 1

Combination SBIRT for Emergency Department Patients Who Drink and Smoke

NCT01595178
COMPLETED Phase 1

Varenicline on Reward Responses and Cognition in Adolescent Smokers

NCT01624428
COMPLETED NA

PET Imaging of mGLuR5 With Drug Challenge

NCT01691092
COMPLETED NA

A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ

NCT01628536
COMPLETED NA

Pivotal Response Treatment for Children With Autism Spectrum Disorders

NCT01908686
COMPLETED Phase 1

Social Cognitive Training for Psychosis: Treatment Development

NCT01579422
COMPLETED NA

Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's

NCT02502045
COMPLETED NA

New Haven MOMS Partnership

NCT01665872
COMPLETED Phase 2

Tobacco Approach Avoidance Training for Adolescent Smokers-2

NCT01625637
COMPLETED NA

Stress Management Among Latinos With Type 2 Diabetes

NCT01578096
TERMINATED Phase 2

Zonisamide for Heavy Drinkers With Bipolar Disorder

NCT01566370
COMPLETED Phase 4

Guanfacine in Children With Tic Disorders

NCT01547000
COMPLETED Early Phase 1

Program for Caregivers Involved With Mental Health Services

NCT01872585
COMPLETED Phase 1

Testosterone Replacement for Male Opioid Agonist Maintained Patients

NCT01873989
COMPLETED NA

Internet Treatment for Weight Loss in Primary Care

NCT01558297
COMPLETED NA

Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients

NCT01645033
COMPLETED Phase 1

Yoga for Pain and Opioid Dependence

NCT01590251
COMPLETED Phase 1

Ketamine for Depression and Alcohol Dependence

NCT01551329
COMPLETED NA

Integrated Brain, Body and Social Intervention for Attention Deficit Hyperactivity Disorder (ADHD)

NCT01542528
COMPLETED NA

Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease

NCT01556113
TERMINATED Phase 2

Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

NCT01465230
COMPLETED NA

HIV, Buprenorphine, and the Criminal Justice System

NCT01550341
COMPLETED NA

Examination of Glutamate and mGluR5 in Psychiatric Disorders

NCT02727972
COMPLETED NA

4D Image-Guided Partial Breast Radiation in Stage 0 and l Breast Cancer

NCT01646346
COMPLETED Phase 1

Computer Based Training in Cognitive Behavioral Therapy Web-based

NCT01442597
COMPLETED Phase 1

Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes

NCT01855490
COMPLETED NA

Prevention of Seroma Formation and Wound Complications Using NPWT Devices

NCT02147288
COMPLETED NA

Effect of a Medium Chain Triglyceride Supplemented Diet on Cognitive Function and Brain Activation in Type 1 Diabetes.

NCT01315171
COMPLETED Phase 2

Naltrexone and Memantine Effects on Alcohol Drinking Behaviors

NCT01519063
COMPLETED NA

Cognitive Effects of Atomoxetine in Humans: Genetic Moderators

NCT01498549
COMPLETED Phase 4

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
COMPLETED Phase 2

Functional Neuroimaging of Alcoholism Vulnerability (PIT)

NCT01585168
COMPLETED Early Phase 1

Cannabinoid Modulation of Pain

NCT01595620
← Previous Page 22 of 30 Next →

Phase Distribution

PhaseTrial count
Phase 1 312
Phase 2 267
Phase 3 52
Phase 4 47

Therapeutic Areas

Opioid Use Disorder 19
Obesity 15
Alcohol Use Disorder 13
Heart Failure 13
HIV 13
Type 1 Diabetes 10
Schizophrenia 10
Healthy 10
Nicotine Dependence 9
Major Depressive Disorder 9

What is open in the Yale University pipeline

254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).

Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).

Top condition: Opioid Use Disorder (19 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Yale University: open-pipeline peers nationwide

Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Yale UniversityWashington University School of MedicineJohns Hopkins UniversityUniversity of PennsylvaniaNovartis PharmaceuticalsNYU Langone HealthCSL BehringPenn State UniversityUniversity of Hawaii
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,492 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Yale University page

1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.

  • 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.